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Background: Mycosis Fungoides (MF) is an indolent lymphoproliferative disorder affecting
dermis caused by abnormal proliferation of CD4+ T-cells. Radiation therapy is the most effec-
tive  modality of treatment for MF which offers cure in limited stage disease and desirable
palliation in advance stage disease. Treating entire skin having many  curved surfaces and
folds  with radiation is the real challenge for the radiation oncologist. Many techniques, dose
schedules and modiﬁcations in total skin electron irradiation (TSEI) have been tried since
1950s. TSEI treatment is a very time consuming, inconvenient and physically challenging to
both  patient as well as oncologist.
Aim: At our center TSEI was performed since 1983 with conventional linear accelerator where
the  treatment time was prolonged beyond two hours, which was very difﬁcult or the patient,
oncologist, technical ofﬁcer and eating away the machine time hampering the treatment
of  other patients. From 1998 we shifted to high dose rate (HDR) mode, in order to bring
down the treatment time of a single patient every day from two and half hour to 15 min.
The  reduction of treatment time increases patient compliance and at the same time saved
machine time.
Materials and methods: Between 1998 and 2003, eleven pathological diagnosed MF patients
were treated using HDR TSEI. All the patients were male between 40 and 70 years of age,who had the history of having the disease for 7–22 months. Four patients had T2 and seven
e disease with more than 90% skin surface involvement. TSEI was per-patients had T3 stagformed with 4 MeV electrons with a daily fraction size of 120 cGy to a total dose of 36 Gy. At
the  end of 36 Gy, boost dose of 10 Gy was delivered to self shielding regions like sole, scalp
and  perineum. Considering the treatment related toxicities and consequent treatment inter-
ruptions, in the ﬁrst seven patients, the last four patients were treated using similar HDR
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TSEI technique with modiﬁed treatment schedule, where the treatment was given on an
alternate day basis following 2nd week of initiation of treatment.
Results: The patients were followed over a period of 144 months with a median of 72 months.
Nine  patients are alive without any evidence of disease, one patient relapsed and one died
due  to progression of disease. The most common radiation related morbidities are erythema,
skin blisters, various degree of desquamations, swelling of joints (specially small joints) etc.
which are controlled by treatment interruptions and conservative measures. By modifying
the  treatment schedule, the incidence of toxicity as well as treatment interruptions were
brought down.
Conclusions: We  can conclude that HDR-TSEI is an excellent and safe therapeutic modality
for  the patients with MF both curative as well as palliative without any added toxicity proﬁle,
provided patient positioning is done properly.







































ycosis Fungoides is a low grade chronic lymhoproliferative
isorder of T-lymphocytes arising out of skin, usually hav-
ng an indolent course, caused by abnormal proliferation of
D4+ T cells.1 MF  itself is often an epidermotropic disor-
er characterized by evolution of patches into plaques and
umors composed of small- to medium-sized skin-homing T
ells, some (or, rarely all) of which have convoluted, cerebri-
orm nuclei. Individuals affected are usually in their 50s or
0s. Children are rarely affected. According to the Leukemia
nd Lymphoma Society in the United States, there are about
500 new cases of cutaneous T-cell lymphoma every year.
he overall incidence of MF  is about 4 per 100,000.2,3 In
ndia there are no accurate statistics regarding the inci-
ence of MF. The frequency of occurrence of cutaneous
ymphomas was found to be 0.7 per 100 biopsy speci-
ens. In another Indian study, the frequency of occurrence
f MF  to be 73% of all lymphomas.4 Over the past three
ecades the incidence rate of MF  is showing an increas-
ng trend, may be because of improved diagnostic tools
nd techniques. However the exact incidence may still be
nderreported because of difﬁculty in diagnosis or misdiag-
osis.
The principal prognostic factors are the (1) extent and
hase of disease; (2) lymphadenopathy and visceral involve-
ent and (3) presence of lymphoma cells in the peripheral
irculation.5 In the early stage of disease, the prognosis has
lso been independently associated with pathobiological ﬁnd-
ngs like depth of cutaneous inﬁltration, total contiguous and
on-contiguous inﬁltrative cell density, the proportion of reac-
ive CD8+ cells and dermal inﬁltrate. However the prognosis is
enerally poor in advanced stage of the disease. Transforma-
ion of MF  cells to large-cell lymphoma also implies a poor
rognosis.6–9
The classical MF  progresses through ﬁve distinct phases;
remycotic, patch, plaque, tumor and erythroderma. The
ymptoms vary according to the stage of the disease and
egree of skin involvement. Patients with stage 1A and 1B dis-
ase (patch and plaque stage only) account for about 75% of
ll new patients. Therefore, early-stage disease that is mostlyrights reserved.
localized in the skin has an excellent chance of cure with skin-
directed therapies alone. Radiation therapy remains most
effective form of curative as well as palliative form of treat-
ment. The cutaneous lesions are extremely radioresponsive
and a dose–response relationship has been demonstrated.10–13
The complete remission rates with this therapy may be as
high as 90–100% in localized lesions. Cotter et al. have even
demonstrated 100% remission with a radiation dose in excess
of 30 Gy.14 Wilson et al. have reported a remission rate of 97%
with external beam radiotherapy.15 Therefore it is extremely
important to deliver a total dose of 36–40 Gy of radiation over
a period of 10–11 weeks, not having too many  treatment
interruptions in-between because of the treatment related
toxicities.
Between 1985 and 1998 we had treated 14 patients of MF.
TESI was carried out using a high-energy Linear Accelera-
tor (Clinac 20) with 6 MeV electrons in conventional method.
The patients were made to stand on a stationary platform
with the legs wide apart behind a polystyrene screen, which
was used for reducing the beam energy from 6 MeV  to 4 MeV
at a distance of 10 feet from the iso-center of the accelera-
tor. Two large overlapping ﬁelds were used to irradiate the
whole length of the body. The central axis of the ﬁelds pointed
15◦ upwards and downwards from the horizontal plane to
minimize photon contamination, as described in the Stan-
ford technique. All the patients were treated in six positions
(anterior, posterior, left anterior oblique, left posterior oblique,
right anterior oblique and right posterior oblique). All The 12
ﬁelds (6 upper half and 6 lower half of body) were treated
every day. The total dose of radiation varied from 8 to 36 Gy
with a daily fraction size of 120 cGy, given over 5 days in a
week. Since beginning of TSEI the eyes and nails were shielded
with a 3 mm-thick lead. A supplementary boost dose of 10 Gy
was given to self-shielding areas like the scalp, perineum and
soles.16
Problems encountered with conventional TSEI: The patient
positioning behind polystyrene screen remained too much
complicated and as the dose rate of the Clinac 20 was less, the
total treatment time for each patient was taking more  than
two hours every day. For the patient standing eyes blinded for
two long hours was the real challenge, therefore ending up
with less patient compliance.
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2.  HDR  TSEI:  materials  and  methods
(Indian  experience)
Between 1998 and 2004 eleven patients were treated with TSEI
using Electa (SL-20) dual energy linear accelerator having a
special attachment which delivers electron at a very high dose
rate (30 Gy/min) at the iso-centere.17 The high dose rate mode
delivered 4 MeV  electron beam with acceptable beam unifor-
mity, adequate depth dose while maintaining a low-level of
X-ray contamination. All the patients were male between 40
and 70 years of age, who  had the history of having the dis-
ease for 7–22 months. Four patients had T2 and 7 patients had
T3 stage disease with more  than 90% skin surface involve-
ment. In three patients the lesions were conﬂuent, ulcerated
and bleeding on manipulation. Extra-cutaneous sites were
not involved in any of the patients. The treatment technique
remained same as in conventional TSEI except no polysterene
screen was used. All patients were administrated a total dose
of 36 Gy over 9–14 weeks with a daily fraction of 120 cGy, with
a booster dose of 10 Gy to scalp, perineum and sole. Thermo
luminescent dosimeter (TLD) measurements of the prescribed
skin dose were obtained at the lateral margins, dorsum of the
foot, perineum and scalp to see if there are certain hot spots
over any skin curvatures. The patients were evaluated accord-
ing to a ﬁxed schedule, given hydration before treatment and
advised to take high calorie diet throughout the treatment.
All the routine investigations except the chest X-ray were per-
formed biweekly throughout the treatment period.
Advantages of HDR TSEI: The use of the polystyrene screen
was not required. The treatment time for each individual
patient drastically came down  to 15 min  only from more  than
two hours in conventional method, thereby increasing compli-
ance and comfort of the patient, oncologist and technologist.
Reducing treatment time also keeps the machine free to be
used for other patients.
Problems encountered with HDR TSEI: But there were treat-
ment interruptions for various duration in all the patients
because of radiation-associated morbidities such as decrease
in hemoglobin and total leucocytes count, development of
cutaneous blisters, moist desquamation of the skin (grade II-3,
grade III-2) and the poor general condition of the patients. The
period of treatment interruptions ranged from 5 to 11 days and
occurred in batches of 2–3 during the entire treatment.
As the end-response to radiation therapy in MF is depen-
dant on the total radiation dose and duration of treatment,
prolonged overall treatment duration can spare the tumor
cells and lower the chance of cure, where as delivering the
total dose over a shorter duration provides greater radiobio-
logical beneﬁt and offers better tumor control.10,11 Hence, it is
very important not to have many  treatment interruptions.
Modiﬁcation of the TSEI schedule: In order to reduce HDR-
TSEI related toxicities and treatment interruptions, last
four patients were treated with a modiﬁed fractionation
schedule.18 The treatment was carried out using a HDR mode
delivering 4 MeV  electron at a dose rate of 30 Gy/min at isocen-
ter. In this protocol the patients were treated with similar
Stanford Technique, 120 cGy/ﬁeld/day, to a total dose of 36 Gy.
Both halves of body received treatment at each session. But
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delivered 5 days/week for ﬁrst two weeks and then on alter-
nate days until completion of total radiation dose. At the end
of the treatment, a booster dose of 10 Gy was delivered to self
shielding areas such as sole, scalp and perineum. Rest of the
evaluation and follow up protocols were similar to previous
group of patients.
Advantages of modifying the treatment schedule: there were
absolutely no treatment interruptions and therefore the total
radiation dose could be delivered within 9–10 weeks which
helped in obtaining better tumor control (Table 1).
3.  Results
The patients were followed up at an interval of every 6 weeks
in the ﬁrst year, every 3 months during the second year
and every 6 months there after following TSEI over a period
of 144 months with a median of 72 months. Nine out of
eleven patients had complete remission both clinically and
histopathologically following TSEI (Table 2). In the other two
patients the lesions healed with a few ulcers. In one patient the
lesions relapsed on the trunk after 10 months and in the other
patient who did not received the boost treatment, the lesions
relapsed over the eyelid and the perineum after 4 months.
He was treated with 10 Gy of radiation dose to these regions.
Out of these two, one patient subsequently progressed, lost
to follow up and the other one died. The most common radi-
ation related morbidities are erythema, skin blisters, various
degree of desquamations, swelling of joints (specially small
joints) etc. which are controlled by treatment interruptions
and conservative measures. One patient developed pericardial
effusion leading to generalized edema; who was managed for
cardiac disease and treated like other patients. At the end of
12 years (1998–2010), all nine patients were alive without any
evidence of disease.
The modiﬁcation in the treatment protocol resulted in
much less occurrence of radiation associated toxicities like
wet desquamation, swelling of joints etc. with no treatment
interruptions. The toxicities were limited to small blisters and
mild swelling and pain of small joints. All the patients could
complete the radiation treatment of total dose of 36 Gy within
10 weeks, compared to 14 weeks by conventional method.
4.  Discussions
Although radiation as a therapy was used for the treatment
of localized/limited lesions of MF in 1902, large areas of skin
or the entire skin with low-energy X-rays or electrons could
not be treated due to lack of equipment and technical short-
comings. TSEI is still a technically and practically challenging
procedure. Hence, not many  centers around the world use it.
The set-up for performing TSEI requires a proper infrastruc-
ture, and the optimum management of MF patients requires a
close collaborative efforts amongst the radiation oncologist,
medical physicist and dermatologist. A variety of technical
and clinical issues related to TSEI and its effects were reviewed
by Reavely et al.19 A model of TSEI treatment using the ‘Six
dual ﬁeld’ technique was reviewed by Faz D et al.20 In a study
by Hoppe et al, the initial complete response ranged from 86%
in early-stage diseases to 44% in the tumor stage. Kuten et al.
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Table 1 – Comparison of treatment schedules.
HDR TSEI Modiﬁed alternate day HDRTSEI
Total radiation dose, Gy 36 36
Total treatment duration, wks 14 10
Treatment schedule 5 fractions/wk until completion of total dose 5 fractions/wk for 2 wks, then 3 fractions/wk







































Edema of the limbs ++ 
Treatment interruptions 2–3 
ave reported a cure rate of 95–100% with TSEI.21 Ysebeart
t al. have described that TSEI produces excellent results in T1,
2 stage of MF.22 The probability of complete remission is high
ith TSEI it and offers good palliation in advanced diseases.23
egardless of the technique used, the most important factors
o get the best results in TSEI remain the electron energy,
hich should be 4 MeV  and the total dose which should be
ore than 30 Gy.16,17,24 The procedure has been modiﬁed sev-
ral times during the process of developing the TSEI program
t Stanford University to make it more  technically reﬁned and
linician as well as patient friendly, which was widely accepted
y many  centers and at the same time many  centers tried to
mprove upon the dose-schedule of the technique.
We have been using this therapeutic modality in MF
atients since 1985, and in our experience TSEI is an excel-
ent treatment modality in both early and advance diseases.
he total treatment time taken for an individual setting was
bout 2 h when the patient is being treated with conventional
ay but such prolonged treatment time many  times become a
indrance for proper execution of TSEI, particularly in case of
lderly patients they cannot stand for such a long time with
yes closed and also maintain proper posture and position.
his difﬁculty was being addressed when treatment is exe-
uted by high dose rate (HDR) mode and the treatment time
or an individual patient is drastically reduced to only about
5 min, which is signiﬁcantly shorter than delivering TSEI by
onventional mode, while retaining proper functioning of the
ccelator dosimetry systems and interlocks. A dose of 4 MeV
s usually used to treat epidermal and dermal lesions homo-
eneously. As most of the dose (80%) is delivered at a depth of
 cm and less than 5% beyond 2 cm,  structures below the deep
ermis are spared. Shadowed regions like the scalp, perineum,
ole and other skin folds are boosted later with local electron
elds.It is acknowledged that any TSEI program development is
eavily dependent on the speciﬁc technique chosen, the par-
icular equipment on which it is carried out and the facility
Table 2 – Results of HDRTSEI (n = 11).







where it will be implemented. The techniques themselves are
often complex with concomitant hazards and most are time
consuming to develop and carry out on a routine basis. A rig-
orous quality assurance program should be an integral part
of especially HDR TSEI, because of high electron dose rates at
isocenter are usually employed to minimize treatment time
may produce undesirable side effects if patient set up is not
done properly.
The skin of patients treated with TSEB irradiation at doses
>10 Gy usually develops mild erythema and dry desquama-
tion that may become uncomfortably symptomatic. Lesions
frequently become more  erythematous than clinically nor-
mal  areas during the early phase of treatment and may
later become hyperpigmented. At higher doses (>25 Gy),
some patients experience transient swelling of the hands,
edema of the ankles, and occasionally large blisters that may
necessitate local shielding or temporary discontinuation of
therapy. Unless hair and nails are shielded, loss of these
skin appendages invariably occurs by the end of treatment,
but they regenerate within 4–6 months. In our treatment
schedule, the eyes and nails were shielded from day one of
the treatment. Chronic cutaneous damage from TSEI irradi-
ation is unusual at doses of <10 Gy and is acceptably mild
through 25 Gy. Superﬁcial atrophy with wrinkling, telang-
iectases, xerosis, and uneven pigmentation are the most
common changes. With higher total doses, frank poikilo-
derma, permanent alopecia, skin fragility, and subcutaneous
ﬁbrosis are more  likely to occur but are uncommon. In gen-
eral, the nature and severity of acute and chronic radiation
effects are a function of technique, fractionation scheme, total
dose, concomitant use of topical or systemic cytotoxic drugs,
previous treatments, and the condition of the skin before irra-
diation. In order to avoid these toxicities, the patients have
to be informed and explained properly regarding the mainte-
nance of correct positions particularly when treated with HDR
mode.
Many modiﬁcations to the technique and dose fraction-
ation have been done to obtain better results, which have been
documented in many  studies.25–28 In 1971, Fuks and Bagshaw
presented therapeutic results in 107 patients treated with 2.5-
MeV  electrons at Stanford University. They increased the total
dose to 30 Gy and presented evidence indicating that increas-
ing the total dose also have an impact on post treatment
disease-free intervals, thereby justiﬁed a more  aggressive ther-
apeutic approach than that used previously.
In a study by Rosenblatt et al. analyzed the inﬂuence of total
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rate, survival and skin toxicity of patients with MF  treated with
TSEI found that a reduction of the total dose and dose-per-
fraction resulted in an acceptable CR rate and a signiﬁcantly
lower toxicity. But in our experience it was noticed that when
the patients were treated with a dose less than 30 Gy, the dis-
ease control rate was not good. Disease control and late skin
toxicity is directly related to the dose–fractionation sched-
ule. We  have demonstrated that HDR TSEI increases patient
compliance with reduced treatment time and modiﬁcation
of treatment schedule decreases treatment related toxicities
allowing to deliver total radiation dose above 30 Gy and obtain-
ing better disease free interval.
5.  Conclusions
As a conclusion, we can submit that TSEI is an excellent thera-
peutic modality for the patients with MF  both curative as well
as palliative. HDRTSEI reduces treatment time considerably
making it more  users friendly. As the treatment is delivered
over a short period of time, stress must be given on proper
patient positioning in order to avoid hot spots due to overlap-
ping of radiation ﬁelds. The severity of acute toxicity can be
minimized by proper dose-fractionation schedules.
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